TG Therapeutics Given Buy Rating at Brean Capital (TGTX)
A number of other firms have also recently commented on TGTX. Analysts at Roth Capital raised their price target on shares of TG Therapeutics to $25.00 in a research note on Tuesday, July 22nd. They now have a “buy” rating on the stock. Separately, analysts at MLV & Co
raised their price target on shares of TG Therapeutics from $10.00 to $16.00 in a research note on Wednesday, July 2nd. They now have a “buy” rating on the stock. Finally, analysts at Ladenburg Thalmann set a $18.00 price target on shares of TG Therapeutics in a research note on Monday, June 16th.
TG Therapeutics (NASDAQ:TGTX) traded up 5.32% on Friday, hitting $7.92. 293,617 shares of the company’s stock traded hands. TG Therapeutics has a 52-week low of $2.97 and a 52-week high of $11.56. The stock has a 50-day moving average of $8.91 and a 200-day moving average of $6.97. The company’s market cap is $301.9 million. TG Therapeutics also saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 2,896,549 shares, a growth of 39.4% from the July 15th total of 2,077,751 shares. Currently, 10.2% of the company’s shares are short sold. Based on an average daily trading volume, of 533,819 shares, the days-to-cover ratio is presently 5.4 days.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Tuesday, July 22nd. The company reported ($0.36) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.28) by $0.08. On average, analysts predict that TG Therapeutics will post $-1.28 earnings per share for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.